GMAB Earnings & Financial Statements
Genmab A/S
$36.89
+$0.32(+0.88%)
61
Overall
60
Value
75
Tech
50
Quality
Market Cap
$23.02B
Volume
2.69M
52W Range
$23.62 - $40.17
Target Price
$43.22
GMAB earnings and financial statements: Genmab A/S's income statement, balance sheet and cash flow statement, annual and quarterly.
GMAB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2019 |
|---|---|---|---|---|---|
| Revenue | $3.72B | $3.12B | $16.47B | $14.51B | $5.37B |
| Cost of revenue | $238.00M | $143.00M | $226.00M | - | - |
| Operating income | $1.06B | $972.00M | $5.32B | $6.27B | $2.64B |
| EBITDA | $1.54B | $1.68B | $6.28B | $8.65B | $2.72B |
| Net income | $963.00M | $1.13B | $4.35B | $6.81B | $2.17B |
| EPS (diluted) | - | $121.36 | $66.02 | $8.37 | $3.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2019 |
|---|---|---|---|---|---|
| Total assets | $12.87B | $6.41B | $35.29B | $30.12B | $15.14B |
| Total liabilities | $7.03B | $1.28B | $3.68B | $2.84B | $1.10B |
| Shareholders’ equity | $5.85B | $5.14B | $31.61B | $27.28B | $14.05B |
| Cash and equivalents | $1.72B | $1.38B | $14.87B | $9.89B | $149.00M |
| Long-term debt | $5.13B | $131.00M | $680.00M | $523.00M | $155.00M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2019 |
|---|---|---|---|---|---|
| Operating cash flow | $1.19B | $1.13B | $7.38B | $3.91B | $1.33B |
| Capital expenditure | - | - | - | - | -$111.00M |
| Free cash flow | -$6.08B | $1.08B | $7.00B | $3.60B | $1.22B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GMAB | $36.89 | +0.9% | 2.69M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |